Chinese biopharmaceutical company Mabwell (SH:688062) announced on Tuesday that the first patient has been dosed in the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scarring in China.

With this milestone, 9MW3811 becomes the world's first IL-11 targeting drug candidate to initiate clinical trials for pathological scarring.

The new trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring. The first patient was dosed at the Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Previously, 9MW3811 had completed Phase I trials in healthy subjects in Australia and China, with results showing a good safety profile and a half-life of more than one month.